Zhang Ingrid purchased $163K of LEGN
Zhang Ingrid (Chief Executive Officer) purchased 20,000 shares of Legend Biotech Corp (LEGN) at $8.16 ($0.16M total) on 2026-11-17.
Legend Biotech Corp
Legend Biotech is a global biopharmaceutical company that discovers, develops, manufactures and commercializes cell therapies for cancer and other indications. It operates through subsidiaries primarily in the United States, China and Europe and is headquartered in Somerset, New Jersey. Its approximately 2,900 employees work across the United States, China and Europe. Legend Biotech’s lead product, CARVYKTI, is an autologous CAR-T cell therapy called cilta-cel, developed with Janssen for multiple myeloma. The companies share development, production and commercialization costs and profits or losses equally outside Greater China; in Greater China, Legend Biotech assumes 70% of costs and retains or bears 70% of pre-tax profits or losses. Legend Biotech also develops a portfolio of earlier-stage cell therapy candidates for cancers and autoimmune conditions. It has a license agreement granting Novartis worldwide rights to develop, manufacture and commercialize certain cell therapies, with tiered royalties and potential milestone payments.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Zhang Ingrid (Chief Executive Officer) purchased 20,000 shares of Legend Biotech Corp (LEGN) at $8.16 ($0.16M total) on 2026-11-17.
Salovey Peter purchased 20,000 shares of Legend Biotech Corp (LEGN) at an average of $9.16 ($8.95–$9.38, $0.18M total) across 2 trades over 2026-11-12 to 2026-11-13.
Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform, setting a $20 price target, implying 14.3% upside from the Nov 13 close of $17.50. Recent analyst notes on the company have price targets ranging from $25 to $61.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LEGN (Legend Biotech Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent LEGN coverage spans financial news, insider activity and earnings.
In the last 30 days, LEGN insiders filed 3 SEC Form 4 transactions — 3 purchases ($346K) and no sales. The most active reporter was Salovey Peter with 2 filings.
Insider buying by the CEO is modestly supportive sentiment, but it is not a fundamental catalyst and lacks a 10b5-1 plan context.
Insider buying can be read as mildly supportive, but this is a small, non-guidance insider transaction with limited standalone price impact.
Analyst downgrade and lower price target suggest weaker outlook.
Oppenheimer kept its 'Perform' rating on Legend Biotech but cut its price target to $25 from $40, a 37.5% reduction. This implies a 22.5% upside from the Nov 10 close of $20.41. Other recent analyst targets for the company range from $43 to $61.
Morgan Stanley kept its Overweight rating on Legend Biotech but cut its price target to $43 from $49, a 12.2% reduction. The new target suggests a 110.7% upside from the Nov 10 closing price of $20.41, according to the firm.
AlphAI scores every news story that mentions LEGN with an AI model for sentiment and relevance, and aggregates insider trades from Legend Biotech Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zhang Ingrid (Chief Executive Officer) purchased 20,000 shares of Legend Biotech Corp (LEGN) at $8.16 ($0.16M total) on 2026-11-17.
Salovey Peter purchased 20,000 shares of Legend Biotech Corp (LEGN) at an average of $9.16 ($8.95–$9.38, $0.18M total) across 2 trades over 2026-11-12 to 2026-11-13.
Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform, setting a $20 price target, implying 14.3% upside from the Nov 13 close of $17.50. Recent analyst notes on the company have price targets ranging from $25 to $61.
Oppenheimer kept its 'Perform' rating on Legend Biotech but cut its price target to $25 from $40, a 37.5% reduction. This implies a 22.5% upside from the Nov 10 close of $20.41. Other recent analyst targets for the company range from $43 to $61.
Morgan Stanley kept its Overweight rating on Legend Biotech but cut its price target to $43 from $49, a 12.2% reduction. The new target suggests a 110.7% upside from the Nov 10 closing price of $20.41, according to the firm.
Barclays kept Legend Biotech's rating at Overweight but reduced its price target to $61 from $68. The new target suggests a 198.9% upside from the Nov 10 close of $20.41, according to the bank.
RBC Capital kept Legend Biotech's rating at Outperform but reduced its price target to $50 from $56, a 10.7% cut. The new target suggests a 145.0% upside from the stock's Nov 10 close of $20.41.
Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.
Legend Biotech Corp (LEGN) furnished an SEC Form 6-K — earnings release. Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights • CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million • Half of CARTITUDE-2 Cohort A patients remained alive and progress
Legend Biotech reported 100% response rates in 8 patients treated with LB2501 at dose level 2, with responses lasting up to 5 months. The data was presented in abstracts for the ASH 2026 conference, showing a CITADEL IEC-parkinsonism rate of 1.6% with preemptive steroids. The next catalyst is the full ASH 2026 presentations, including more Phase 1 data for LB2501 and LUCAR-G39D.